Amplia Therapeutics Ltd has released a press release.
AMP945 Pre-IND Meeting Outcome
Filed with ASX ·
6ix hasn’t read this filing yet.
Amplia Therapeutics Ltd. on 6ix
In the deck
Earlier from Amplia Therapeutics
- Quarterly Activities and Cashflow Reports - March 2022 Qtr
- Ethics Clearance Phase 2 Trial - Pancreatic Cancer Patients
- AMP945 Improves Survival in Human Pancreatic Cancer Model
- Quarterly Activities and Cashflow Reports - Dec 2021 Qtr
- Amplia Completes Manufacture of AMP945 for Planned Trials
Later from Amplia Therapeutics
- Amplia Receives Second Ethics Clearance for Phase 2 Trial
- Preliminary Final Report and Annual Report YE 31 March 2022
- AMP945 Shows Efficacy in Model of Lung Fibrosis
- Quarterly Activities and Cashflow Reports - June 2022 Qtr
- First Patient Recruited to ACCENT Trial in Pancreatic Cancer
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics